The blue-chip FTSE 100 slipped by 0.7%, yet it remained on track to achieve its fifth consecutive week of gains. This week saw the benchmark reach an all-time high, buoyed
The blue-chip FTSE 100 slipped by 0.7%, yet it remained on track to achieve its fifth consecutive week of gains. This week saw the benchmark reach an all-time high, buoyed
The Telegraph reported that Treasury borrowing has already shot past official forecasts made in the Budget in a blow to Rachel Reeves’s plans to ramp up spending. Britain has already borrowed
Mendell Helium (AQSE:MDH) provided an overview of M3 Helium Corp.’s assets following a visit in October 2024 by Nick Tulloch, Chief Executive Officer of the Company, to Kansas, USA.
Feedback (FDBK) is a critical Healthcare communications technology developer announced a collaboration with a specialist clinical IT firm with offices in the UK, UAE and South Africa, Vertex. The agreement enables
Ondo Insurtech (ONDO), a company in claims prevention technology for home insurers, has been informed by Mark Wood (Chairman) and Craig Foster (Chief Executive) of the following share purchases. Mark Wood
MicroSalt (SALT), a company commercialising a patented technology to produce full-flavour low-sodium salt, continues to expand its reach of SaltMe! low sodium crisps with a new placement on Thrive Market, an
Sean Heathcoat highlighted the completion of an updated economic study by Erudite Strategies on the Henkries Project, which included revised operating and capital cost estimates based on a 1979 feasibility study.
AIM Again
Character Group (CCT) reported interims to February and while revenue is unchanged at £57.4m, its PBT increased to £2.1m from last years depressed £0.2m. Over the years they have built a
George Roach, the CEO of Premier African Minerals, provided a walkthrough and operational update from their Zulu site. Here’s a summary of the key points covered in the video
Poolbeg Pharma (POLB), a biopharmaceutical company, announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced CRS.
Yesterday Ananda Developments (AQUIS: ANA), the company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of chronic, complex inflammatory pain conditions, announced its unaudited management statements